Develops targeted therapies and immuno-oncology agents for the treatment of various cancers.
Apollomics, Inc. is a dynamic clinical-stage biopharmaceutical firm dedicated to advancing oncology therapies that leverage both the immune system and targeted molecular pathways to combat cancer. Established in 2015 and headquartered in Foster City, California, the company specializes in developing a diverse portfolio of innovative treatments. At the forefront of their pipeline is Vebreltinib (APL-101), an orally active, highly selective c-Met inhibitor currently undergoing Phase 2 clinical trials for non-small cell lung cancer. Additionally, APL-102, a small molecule Multiple Tyrosine Kinase Inhibitor, is progressing through Phase 1 clinical trials targeting various aberrantly activated kinases in cancer cells.
Apollomics is also advancing APL-122, a promising tumor inhibitor aimed at the ErbB1/2/4 signaling pathways, which is undergoing Phase 1 dose escalation trials for brain cancers. The company's robust pipeline includes uproleselan (APL-106), currently in Phase 3 clinical trials for relapsed or refractory acute myeloid leukemia (AML), with additional Phase 2/3 studies focusing on newly diagnosed older adults with AML. Furthermore, APL-108, a second-generation E-selective inhibitor, has completed Phase 1 clinical trials targeting both liquid and solid cancers.
Beyond these advancements, Apollomics is actively developing a range of preclinical stage immuno-oncology candidates such as APL-501, APL-502, APL-801, and APL-810. These efforts underscore Apollomics' commitment to expanding treatment options in oncology, with a portfolio encompassing tumor inhibitors, anti-cancer enhancers, and innovative immune-oncology therapies designed to address critical unmet medical needs in cancer care.